新辅助化疗联合参附注射液治疗头颈鳞癌疗效观察

Neoadjuvant chemotherapy plus Shenfu Injection for treating head and neck squamous cell carcinoma

目的:观察新辅助化疗联合应用参附注射液在治疗头颈鳞癌中的疗效和毒副作用。方法:将44例头颈鳞癌患者随机分成2组,参附联合化疗组行参附注射液联合化疗,单纯化疗组行单纯化疗,就其临床疗效、毒副作用进行对比研究。结果:两组病员新辅助化疗疗效(χ2=0.014,P>0.05)、治疗前后体质量(t=2.018,P>0.05)及心脏毒性(χ2=0.516,P>0.05)均未见显著性差异。而参附注射液联合化疗组在改善KPS评分(χ2=4.207,P<0.05)、减轻骨髓毒性(χ2=4.385,P<0.05)方面较单纯化疗组有显著性差异(P<0.05)。结论:在头颈鳞癌新辅助化疗中联合参附注射液能减轻化疗药物毒副作用、提高患者的生活质量。

Objective： To observe the curative effect and side effect of Neoadjuvant chemotherapy plus Shenfu Injection for treating head and neck squamous cell carcinoma. Methods： Forty-four patients with head and neck squamous cell carcinoma were randomly divided into two groups： one group were treated with neoadjuvant chemotherapy plus Shenfu Injection; the other were treated with neoadjuvant chemotherapy alone. The curative effect and side effect were investigated. Results： There was no significant difference between these two groups in curative effect（χ^2=0.014, P〉0.05）, body weight（t=2.018, P〉0.05）and heart toxicity（χ^2=0.516, P〉0.05）. The group with neoadjuvant chemotherapy plus shenfu injection had higher KPS score（χ^2=4.207, P〈0.05） and less marrow toxicity（χ^2=4.385, P〈0.05） than the other group with neoadjuvant chemotherapy only. Conclusion： Shenfu Injection can improve the quality of life and relieve the side effect caused by chemotherapeutics in the treatment of head and neck squamous cell carcinoma with neoadjuvant chemotherapy.